330 related articles for article (PubMed ID: 15231725)
21. Histamine and prostaglandin E up-regulate the production of Th2-attracting chemokines (CCL17 and CCL22) and down-regulate IFN-gamma-induced CXCL10 production by immature human dendritic cells.
McIlroy A; Caron G; Blanchard S; Frémaux I; Duluc D; Delneste Y; Chevailler A; Jeannin P
Immunology; 2006 Apr; 117(4):507-16. PubMed ID: 16556265
[TBL] [Abstract][Full Text] [Related]
22. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in the goose cerebral cortex.
Zawilska JB; Niewiadomski P; Nowak JZ
Pol J Pharmacol; 2004; 56(2):203-11. PubMed ID: 15156071
[TBL] [Abstract][Full Text] [Related]
23. Characterization and expression of different pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptors in rat ovarian follicles.
Vaccari S; Latini S; Barberi M; Teti A; Stefanini M; Canipari R
J Endocrinol; 2006 Oct; 191(1):287-99. PubMed ID: 17065411
[TBL] [Abstract][Full Text] [Related]
24. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
[TBL] [Abstract][Full Text] [Related]
25. Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland.
Mazzocchi G; Malendowicz LK; Neri G; Andreis PG; Ziolkowska A; Gottardo L; Nowak KW; Nussdorfer GG
Int J Mol Med; 2002 Mar; 9(3):233-43. PubMed ID: 11836629
[TBL] [Abstract][Full Text] [Related]
26. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit LPS-stimulated MIP-1alpha production and mRNA expression.
Pozo D; Guerrero JM; Calvo JR
Cytokine; 2002 Apr; 18(1):35-42. PubMed ID: 12090758
[TBL] [Abstract][Full Text] [Related]
27. Activation of VPAC1 receptors by VIP and PACAP-27 in human bronchial epithelial cells induces CFTR-dependent chloride secretion.
Dérand R; Montoni A; Bulteau-Pignoux L; Janet T; Moreau B; Muller JM; Becq F
Br J Pharmacol; 2004 Feb; 141(4):698-708. PubMed ID: 14744818
[TBL] [Abstract][Full Text] [Related]
28. Long-acting analogue of vasoactive intestinal peptide, [R15, 20, 21, L17]-VIP-GRR (IK312532), protects rat alveolar L2 cells from the cytotoxicity of cigarette smoke.
Onoue S; Endo K; Ohmori Y; Yamada S; Kimura R; Yajima T; Kashimoto K
Regul Pept; 2004 Dec; 123(1-3):193-9. PubMed ID: 15518912
[TBL] [Abstract][Full Text] [Related]
29. Role of vasoactive intestinal peptide in inflammation and autoimmunity.
Gonzalez-Rey E; Delgado M
Curr Opin Investig Drugs; 2005 Nov; 6(11):1116-23. PubMed ID: 16312132
[TBL] [Abstract][Full Text] [Related]
30. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide-38 inhibit IL-10 production in murine T lymphocytes.
Martinez C; Delgado M; Gomariz RP; Ganea D
J Immunol; 1996 Jun; 156(11):4128-36. PubMed ID: 8666779
[TBL] [Abstract][Full Text] [Related]
31. Vasoactive intestinal peptide: the dendritic cell --> regulatory T cell axis.
Delgado M; Gonzalez-Rey E; Ganea D
Ann N Y Acad Sci; 2006 Jul; 1070():233-8. PubMed ID: 16888172
[TBL] [Abstract][Full Text] [Related]
32. VPAC2 receptors mediate vasoactive intestinal peptide-induced neuroprotection against neonatal excitotoxic brain lesions in mice.
Rangon CM; Goursaud S; Medja F; Lelièvre V; Mounien L; Husson I; Brabet P; Jégou S; Janet T; Gressens P
J Pharmacol Exp Ther; 2005 Aug; 314(2):745-52. PubMed ID: 15872042
[TBL] [Abstract][Full Text] [Related]
33. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity.
Ganea D; Delgado M
Crit Rev Oral Biol Med; 2002; 13(3):229-37. PubMed ID: 12090463
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of interferon (IFN) gamma-induced Jak-STAT1 activation in microglia by vasoactive intestinal peptide: inhibitory effect on CD40, IFN-induced protein-10, and inducible nitric-oxide synthase expression.
Delgado M
J Biol Chem; 2003 Jul; 278(30):27620-9. PubMed ID: 12754213
[TBL] [Abstract][Full Text] [Related]
35. Vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide inhibit tumor necrosis factor-alpha production in injured spinal cord and in activated microglia via a cAMP-dependent pathway.
Kim WK; Kan Y; Ganea D; Hart RP; Gozes I; Jonakait GM
J Neurosci; 2000 May; 20(10):3622-30. PubMed ID: 10804204
[TBL] [Abstract][Full Text] [Related]
36. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in LPS-stimulated macrophages.
Delgado M; Ganea D
J Neuroimmunol; 2000 Oct; 110(1-2):97-105. PubMed ID: 11024538
[TBL] [Abstract][Full Text] [Related]
37. Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator.
Gonzalez-Rey E; Varela N; Chorny A; Delgado M
Curr Pharm Des; 2007; 13(11):1113-39. PubMed ID: 17430175
[TBL] [Abstract][Full Text] [Related]
38. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-kappa B-dependent gene activation at multiple levels in the human monocytic cell line THP-1.
Delgado M; Ganea D
J Biol Chem; 2001 Jan; 276(1):369-80. PubMed ID: 11029467
[TBL] [Abstract][Full Text] [Related]
39. Pituitary adenylate cyclase-activating polypeptide (PACAP) ameliorates experimental autoimmune encephalomyelitis by suppressing the functions of antigen presenting cells.
Kato H; Ito A; Kawanokuchi J; Jin S; Mizuno T; Ojika K; Ueda R; Suzumura A
Mult Scler; 2004 Dec; 10(6):651-9. PubMed ID: 15584490
[TBL] [Abstract][Full Text] [Related]
40. The neuropeptides VIP/PACAP and T cells: inhibitors or activators?
Ganea D; Delgado M
Curr Pharm Des; 2003; 9(12):997-1004. PubMed ID: 12678866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
